['Acute coronary syndrome leads to systemic responses, including activation of the sympathetic nervous system, inflammation of atherosclerotic lesions, and changes in the metabolism and gene expressions of remote organs such as spleen, bone marrow, and liver. Clinical trials and experimental studies have demonstrated that therapy with adipose-derived regenerative cells (ADRCs) attenuates myocardial ischemia/reperfusion (I/R) injury. The role of ADRCs in regulating systemic reactions following I/R is unclear.', 'We isolated ADRCs obtained from green fluorescent protein transgenic male mice. Flow cytometry revealed that freshly isolated ADRCs expressed stem cell markers CD90 and Sca-1, and the mesenchymal lineage marker. These cells also exhibited multilineage differentiation into adipogenic, osteogenic, and chondrogenic lineages. Wild-type mice were subjected to 30 min of left ascending coronary ischemia and 24 h of reperfusion. Freshly isolated ADRCs (10⁵ cells) or vehicle (VEH), were administered intravenously through the tail at the time of reperfusion. Compared to VEH, administration of ADRCs significantly reduced circulating troponin levels 24 h after I/R. Using qRT-PCR analysis, we confirmed that I/R-induced increase of factor X mRNA expression in the liver was significantly inhibited by ADRCs compared to VEH.', 'Administration of ADRCs significantly reduced the I/R-induced increase in serum levels of the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-18 seen in mice receiving VEH.'] Do adipose-derived regenerative cells exert beneficial effects on systemic responses following myocardial ischemia/reperfusion?